The Latest Cardiac and Vascular News
Brings over 30 years of experience in cardiovascular clinical research, business development, training, education, and medical affairs Strengthens Xeltis’ leadership team following IDE approval for initiation of US pivotal study for aXess™, its restorative vascular access conduit…
Supports Licensing Partner’s Phase 3 Activities in Acute Heart Failure Supports Licensing Partner’s Phase 3 Activities in Acute Heart Failure
– Collaboration leverages Ascendis’ proprietary TransCon™ technologies and Novo Nordisk’s expertise in cardiometabolic diseases
Acquisition to complement electrophysiology portfolio with solution to advance the treatment of complex atrial fibrillation MARLBOROUGH, Mass., Nov. 4, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire…
— Hospital Outpatient Prospective Payment System reimbursement rate doubled, expanding access to CCTA and supporting the technology’s superior accuracy and efficiency in cardiac care
BURLINGTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) — LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q3 2024 results, announced a $0.16/share quarterly dividend, and provided guidance.
Seasoned medical device executive to lead global commercial execution FREMONT, Calif., Oct. 31, 2024 /PRNewswire/ — Q’Apel Medical (Q’Apel), a private medical device company focused on revolutionizing neurovascular interventions, announced today the appointment of seasoned medical device…
CHICAGO–(BUSINESS WIRE)–GE HealthCare (Nasdaq: GEHC) today reported financial results for the third quarter ended September 30, 2024. GE HealthCare President and CEO Peter Arduini said, “In the third quarter, we reported sales and orders growth of 1% globally. Both sales and orders grew in the mid-single digits excluding China, with […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance. “LivaNova delivered strong revenue and operating income growth in the third quarter” Post this Financial Summary and Highlights(1) Third-quarter revenue of $318.1 million increased 11.2% […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2024 financial results. “Reconciliation of Non-GAAP Adjusted Income (Adjusted EBITDA)” Post this “Our broad-based growth in the third quarter reflects […]
